Summary of Study ST002577
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001662. The data can be accessed directly via it's Project DOI: 10.21228/M8VX33 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002577 |
Study Title | Hydroxyproline Modulates Adaptive PD-L1 Expression and Autophagy |
Study Summary | The immune checkpoint protein PD-L1 plays critical roles in both immune system homeostasis and tumor progression. Impaired PD-1/PD-L1 function promotes autoimmunity and PD-L1 expression within tumors promotes immune evasion. If and how changes in metabolism or defined metabolites regulate PD-L1 expression is not fully understood. Here, using a metabolomics activity screening-based approach, we have determined that hydroxyproline (Hyp) significantly and directly enhances adaptive (i.e., IFN-γ induced) PD-L1 expression in multiple relevant myeloid and cancer cell types. Mechanistic studies reveal that Hyp acts as an inhibitor of IFN-γ-induced autophagic flux, which allows it to regulate this negative feedback mechanism, thereby contributing to its overall effect on PD-L1 expression. Due to its prevalence in fibrotic tumors, these findings suggest that hydroxyproline could contribute to the establishment of an immunosuppressive tumor microenvironment and that Hyp metabolism could be targeted to pharmacologically control PD-L1 expression for the treatment of cancer or autoimmune diseases. |
Institute | Scripps Research Institute/University of California, Los Angeles |
Last Name | Palermo |
First Name | Amelia |
Address | University of California, Los Angeles, CA, USA |
apalermo@mednet.ucla.edu | |
Phone | 8582811389 |
Submit Date | 2023-04-10 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzXML |
Analysis Type Detail | LC-MS |
Release Date | 2023-05-17 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001662 |
Project DOI: | doi: 10.21228/M8VX33 |
Project Title: | Hydroxyproline Modulates Adaptive PD-L1 Expression and Autophagy |
Project Summary: | The immune checkpoint protein PD-L1 plays critical roles in both immune system homeostasis and tumor progression. Impaired PD-1/PD-L1 function promotes autoimmunity and PD-L1 expression within tumors promotes immune evasion. If and how changes in metabolism or defined metabolites regulate PD-L1 expression is not fully understood. Here, using a metabolomics activity screening-based approach, we have determined that hydroxyproline (Hyp) significantly and directly enhances adaptive (i.e., IFN-γ induced) PD-L1 expression in multiple relevant myeloid and cancer cell types. Mechanistic studies reveal that Hyp acts as an inhibitor of IFN-γ-induced autophagic flux, which allows it to regulate this negative feedback mechanism, thereby contributing to its overall effect on PD-L1 expression. Due to its prevalence in fibrotic tumors, these findings suggest that hydroxyproline could contribute to the establishment of an immunosuppressive tumor microenvironment and that Hyp metabolism could be targeted to pharmacologically control PD-L1 expression for the treatment of cancer or autoimmune diseases. |
Institute: | Scripps Research Institute/University of California, Los Angeles |
Last Name: | Palermo |
First Name: | Amelia |
Address: | Los Angeles, CA, USA 90095 |
Email: | apalermo@mednet.ucla.edu |
Phone: | 8582811389 |
Subject:
Subject ID: | SU002679 |
Subject Type: | Cultured cells |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Mammals |
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Time |
---|---|---|
SA258753 | EXP1_S1_RPpos | T0 |
SA258754 | EXP1_S2_HILICneg | T0 |
SA258755 | EXP1_S5_HILICpos | T0 |
SA258756 | EXP1_S4_HILICpos | T0 |
SA258757 | EXP1_S2_HILICpos | T0 |
SA258758 | EXP1_S1_HILICpos | T0 |
SA258759 | EXP1_S3_HILICpos | T0 |
SA258760 | EXP1_S1_HILICneg | T0 |
SA258761 | EXP1_S5_HILICneg | T0 |
SA258762 | EXP1_S2_Rppos | T0 |
SA258763 | EXP1_S4_HILICneg | T0 |
SA258764 | EXP1_S3_HILICneg | T0 |
SA258765 | EXP1_S5_Rppos | T0 |
SA258766 | EXP1_S4_Rppos | T0 |
SA258767 | EXP1_S3_Rppos | T0 |
SA258768 | EXP1_S7_HILICpos | T24 |
SA258769 | EXP1_S10_HILICpos | T24 |
SA258770 | EXP1_S9_HILICpos | T24 |
SA258771 | EXP1_S8_HILICpos | T24 |
SA258772 | EXP1_S6_Rppos | T24 |
SA258773 | EXP1_S6_HILICpos | T24 |
SA258774 | EXP1_S9_Rppos | T24 |
SA258775 | EXP1_S8_HILICneg | T24 |
SA258776 | EXP1_S7_Rppos | T24 |
SA258777 | EXP1_S9_HILICneg | T24 |
SA258778 | EXP1_S7_HILICneg | T24 |
SA258779 | EXP1_S6_HILICneg | T24 |
SA258780 | EXP1_S8_Rppos | T24 |
SA258781 | EXP1_S10_Rppos | T24 |
SA258782 | EXP1_S10_HILICneg | T24 |
SA258783 | EXP1_S14_Rppos | T48 |
SA258784 | EXP1_S11_Rppos | T48 |
SA258785 | EXP1_S12_Rppos | T48 |
SA258786 | EXP1_S13_Rppos | T48 |
SA258787 | EXP1_S15_Rppos | T48 |
SA258788 | EXP1_S11_HILICpos | T48 |
SA258789 | EXP1_S12_HILICpos | T48 |
SA258790 | EXP1_S13_HILICpos | T48 |
SA258791 | EXP1_S12_HILICneg | T48 |
SA258792 | EXP1_S13_HILICneg | T48 |
SA258793 | EXP1_S14_HILICneg | T48 |
SA258794 | EXP1_S15_HILICneg | T48 |
SA258795 | EXP1_S14_HILICpos | T48 |
SA258796 | EXP1_S15_HILICpos | T48 |
SA258797 | EXP1_S11_HILICneg | T48 |
SA258798 | EXP1_S19_Rppos | T72 |
SA258799 | EXP1_S20_Rppos | T72 |
SA258800 | EXP1_S16_Rppos | T72 |
SA258801 | EXP1_S18_Rppos | T72 |
SA258802 | EXP1_S17_Rppos | T72 |
SA258803 | EXP1_S18_HILICneg | T72 |
SA258804 | EXP1_S17_HILICpos | T72 |
SA258805 | EXP1_S20_HILICpos | T72 |
SA258806 | EXP1_S19_HILICpos | T72 |
SA258807 | EXP1_S16_HILICpos | T72 |
SA258808 | EXP1_S20_HILICneg | T72 |
SA258809 | EXP1_S17_HILICneg | T72 |
SA258810 | EXP1_S18_HILICpos | T72 |
SA258811 | EXP1_S19_HILICneg | T72 |
SA258812 | EXP1_S16_HILICneg | T72 |
Showing results 1 to 60 of 60 |
Collection:
Collection ID: | CO002672 |
Collection Summary: | Cell pellets were washed with PBS and stored at -80 C until sample preparation |
Sample Type: | AML cells |
Storage Conditions: | -80℃ |
Treatment:
Treatment ID: | TR002691 |
Treatment Summary: | THP-1 cells stimulated with IFN-gamma |
Sample Preparation:
Sampleprep ID: | SP002685 |
Sampleprep Summary: | THP-1 cells were centrifuged and washed with PBS 3 times. The supernatant was discarded, and 1 mL cold MeOH/ACN/H2O (2:2:1) was added to the cell pellets, vortexed, and sonicated in an ice cold bath for 15 min, 3 times. Samples were kept at – 20 ˚C for 1h, centrifuged (13000 rpm for 15 min, 4˚C). The supernatant was evaporated and reconstituted in ACN/H2O (1:1) (volume normalized to viable cell count). Samples were transferred to glass vials and stored at - 80 ˚C until analysis. |
Combined analysis:
Analysis ID | AN004246 | AN004247 | AN004248 |
---|---|---|---|
Analysis type | MS | MS | MS |
Chromatography type | Reversed phase | HILIC | HILIC |
Chromatography system | Bruker Elute | Bruker Elute | Bruker Elute |
Column | ACQUITY BEH C18 (1.0 × 100 mm, 1.7-μm) | ACQUITY BEH Amide (1.0 × 100 mm, 1.7 μm) | ACQUITY BEH Amide (1.0 × 100 mm, 1.7 μm) |
MS Type | ESI | ESI | ESI |
MS instrument type | QTOF | QTOF | QTOF |
MS instrument name | Bruker Impact II | Bruker Impact II | Bruker Impact II |
Ion Mode | POSITIVE | NEGATIVE | POSITIVE |
Units | counts | counts | Counts |
Chromatography:
Chromatography ID: | CH003153 |
Chromatography Summary: | For RP separation, an ACQUITY BEH C18 column (1.0 × 100 mm, 1.7-μm particle size; Waters Corporation, Milford, MA) was used. Flow was 150 μl/min, and a binary buffer system consisting of buffer A (0.1% FA) and buffer B (0.1% FA in acetonitrile) was used. The gradient for RP was: 99% A for 1 min, 1% A over 9 min, 35% A over 13 min, 60% A over 3 min, and held at 60% A for an additional 1 min. The sample injection volume was 2 μl. |
Instrument Name: | Bruker Elute |
Column Name: | ACQUITY BEH C18 (1.0 × 100 mm, 1.7-μm) |
Column Temperature: | 27 |
Flow Gradient: | 99% A for 1 min, 1% A over 9 min, 35% A over 13 min, 60% A over 3 min, and held at 60% A for an additional 1 min |
Flow Rate: | 150 μl/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% aetonitrile; 0.1% formic acid |
Chromatography Type: | Reversed phase |
Chromatography ID: | CH003154 |
Chromatography Summary: | For HILIC separations, an ACQUITY BEH Amide (1.0 × 100 mm, 1.7 μm, Water Corporation, Milford, MA, USA) was used for the analysis. The gradient for HILIC consisted of 1% A for 1 min, 35% A over 13 min, 60% A over 3 min, and held at 60% A for 1 additional minute. |
Instrument Name: | Bruker Elute |
Column Name: | ACQUITY BEH Amide (1.0 × 100 mm, 1.7 μm) |
Column Temperature: | 27 |
Flow Gradient: | 1% A for 1 min, 35% A over 13 min, 60% A over 3 min, and held at 60% A for 1 additional minute |
Flow Rate: | 150 μl/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 100% aetonitrile; 0.1% formic acid |
Chromatography Type: | HILIC |
MS:
MS ID: | MS003993 |
Analysis ID: | AN004246 |
Instrument Name: | Bruker Impact II |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | The mass spectrometer was calibrated using Sodium Formate peaks, before and post-run (internal calibration). Data were acquired over an m/z range of 50 to 1000 Da in positive and negative ionization mode. Electrospray source conditions were set as follows: end plate offset, 500 V; dry gas temperature, 200°C; drying gas, 6 liters/min; nebulizer, 1.6 bar; and capillary voltage, 3500 V. |
Ion Mode: | POSITIVE |
MS ID: | MS003994 |
Analysis ID: | AN004247 |
Instrument Name: | Bruker Impact II |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | The mass spectrometer was calibrated using Sodium Formate peaks, before and post-run (internal calibration). Data were acquired over an m/z range of 50 to 1000 Da in positive and negative ionization mode. Electrospray source conditions were set as follows: end plate offset, 500 V; dry gas temperature, 200°C; drying gas, 6 liters/min; nebulizer, 1.6 bar; and capillary voltage, 3500 V. |
Ion Mode: | NEGATIVE |
MS ID: | MS003995 |
Analysis ID: | AN004248 |
Instrument Name: | Bruker Impact II |
Instrument Type: | QTOF |
MS Type: | ESI |
MS Comments: | The mass spectrometer was calibrated using Sodium Formate peaks, before and post-run (internal calibration). Data were acquired over an m/z range of 50 to 1000 Da in positive and negative ionization mode. Electrospray source conditions were set as follows: end plate offset, 500 V; dry gas temperature, 200°C; drying gas, 6 liters/min; nebulizer, 1.6 bar; and capillary voltage, 3500 V. |
Ion Mode: | POSITIVE |